Abstract
Ovarian cancer is the most lethal gynecologic malignancy. It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube.Treatment of epithelial ovarian cancer is based on the combination of cytoreductive surgery and combination chemotherapy using taxane and platinum. Although clear cell type is categorized in indolent type, it is known to show relatively strong resistance to carboplatin and paclitaxel regimen and thus poor prognosis compared to serous adenocarcinoma, especially in advanced stages. Irinotecan plus cisplatin therapy may effective for the clear cell adenocarcinoma.The larger expectation for improved prognosis in ovarian carcinoma is related to the use of the new biological agents. One of the most investigated and promising molecular targeted drugs in ovarian cancer is bevacizumab, a monoclonal antibody directed against VEGF. PARP inhibitor is another one. A few recent studies demonstrated positive results of bevacizumab on progression-free survival in ovarian cancer patients, however, investigation of molecular targeting drugs in patients with ovarian cancer are still underway.
Highlights
Ovarian cancer is the most lethal gynecologic malignancy
Clear cell carcinoma and mucinous cadenocarcinoma are classified as type I tumors, but unlike the other type I tumors clear cell and mucinous cell types are often high-grade at presentation and show relatively strong resistance to platinum-based chemotherapy
One interesting observation of this trial was in pegylated liposomal doxorubicin (PLD)-carboplatin arm compared to carboplatin-paclitaxel there was the reduction in the rate of hypersensitive reaction Therapeutic Strategies in Epithelial Ovarian Cancer and this is important information since hypersensitive reactions are reported in the general practice in patients treated with carboplatin up to 25%
Summary
Ovarian cancer is the most lethal gynecologic malignancy. The origin and pathogenesis of epithelial ovarian cancer (EOC) have long been investigated but still poorly understood. Studies have shown that epithelial ovarian cancer is not a single disease but is composed of a diverse group of tumors that can be classified based on distinctive morphologic and molecular genetic features [1]. Treatment of epithelial ovarian cancer (EOC) is based on the combination of surgery and chemotherapy. Over the past three decades, surgical tumor debulking, followed by platinum-based chemotherapy is the standard treatment for advanced ovarian cancer. Response rates and complete responses in advanced disease are >80% and 40-60%, respectively, after first-line treatment with carboplatin and paclitaxel, most patients will eventually relapse with a median progression-free survival of 18 months [2]. Malignant mixed mesodermal tumors (carcinosarcomas) are included in the type
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Experimental & Clinical Cancer Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
